Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10804904 | 0.86 | HTR7 (0.49) | HTR7 | |
| SCHEMBL10804764 | 0.84 | HTR7 (0.62) | HTR7 | |
| SCHEMBL10801866 | 0.84 | HTR7 (0.54) | HTR7 | |
| SCHEMBL29935808 | 0.77 | HTR7 (0.49) | HTR7MAPTHTR2C | |
| SCHEMBL10806301 | 0.76 | — | — | |
| SCHEMBL7086944 | 0.75 | MCHR1 (0.52) | HTR7 | |
| SCHEMBL2075612 | 0.74 | HTR2A (0.61) | HTR7HTR2C | |
| SCHEMBL26553449 | 0.73 | CREBBP (0.43) | HTR7 | |
| SCHEMBL16200125 | 0.73 | HTR7 (0.38) | HTR7 | |
| SCHEMBL7083395 | 0.72 | CREBBP (0.70) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199544-A1 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | disclosed |
| US-20030199542-A1 | Farnesyltransferase inhibitors | WEINSTOCK, STEVEN F. | 2003-10-23 | — | — | US | disclosed |
| EP-0086422-B1 | PHARMACOLOGICALLY ACTIVE PYRAZOLO(4,3-C)PYRIDINES | GRUPPO LEPETIT S.p.A. (IT) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199542-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | HTR7 4405/4885MAPT 1684/4885HTR2C 4763/4885 |
| US-20030199544-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | HTR7 4405/4885MAPT 1684/4885HTR2C 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.